Patent ID: 7019143

Claim:
A process for preparing a compound according to the steps shown in Scheme I: wherein the resulting compound is a compound according to Formula I: wherein, for Formula I: (a) X is selected from the group consisting of (b) R1 is selected from the group consisting of C 3 to about C 5 cycloalkyl, C 1 to about C 2 alkanyl, C 2 to about C 3 linear alkenyl, C 3 to about C 4 branched alkanyl or alkenyl, all such alkyl or cycloalkyl moieties being unsubstituted or substituted with from one to about three fluoro; and phenyl, unsubstituted or substituted with from one to about three fluoro, or with one hydroxy in the 4-position; (c) R8 is selected from the group consisting of fluoro, and chloro; (d) R7 is amino which is attached to a ring carbon of X which is not adjacent to the ring nitrogen, the amino being unsubstituted or substituted with one or two C 1 to about C 3 alkanyl; or aminoalkanyl which is attached to any ring carbon of X and is C 1 to about C 3 alkanyl substituted with one amino, the amino being unsubstituted or substituted with one or two C 1 to about C 3 alkanyl; (e) each R9 is independently selected from the group consisting of hydrogen, C 1 to about C 4 alkanyl, C 2 to about C 6 alkenyl or alkynyl, and a C 3 to about C 6 fused or spirocycle alkyl ring; or one R9 may optionally be selected from the group consisting of hydroxy, C 1 to about C 4 alkoxy, aryl and heteroaryl, all other R9 being hydrogen; all alkyl and aryl portions of R9 moieties being unsubstituted or substituted with one hydroxy or with from one to about three fluoro; and (f) a R7 moiety described in (d) and a R9 moiety described in (e) may optionally be connected thus forming a fused or spirocycle ring with the N-containing ring shown in (a), the fused or spirocycle ring comprising from 2 to about 5 ring carbons and 0 or 1 ring nitrogen; or an optical isomer, diastereomer or enantiomer thereof; a pharmaceutically-acceptable salt, hydrate, or biohydrolyzable ester, amide or imide thereof.